ANRO
Alto Neuroscience, Inc.
NYSE: ANRO · HEALTHCARE · BIOTECHNOLOGY
$23.33
+0.60% today
Updated 2026-10-28
Market cap
$895.50M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-2.31
Dividend yield
—
52W range
$10 – $37
Volume
0.6M
Alto Neuroscience, Inc. (ANRO) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating cash flow | $-9.26M | $-20.39M | $-33.45M | $-47.42M | $-51.77M |
| Capital expenditures | $680000.00 | $732000.00 | $470000.00 | $2.08M | $24000.00 |
| Depreciation | — | — | — | — | — |
| Stock-based comp | $227000.00 | $1.76M | $2.89M | $7.63M | $8.11M |
| Free cash flow | $-9.94M | $-21.13M | $-33.92M | $-49.50M | $-51.79M |
| Investing cash flow | — | — | — | — | — |
| Financing cash flow | — | — | — | — | — |
| Dividends paid | — | — | — | — | — |
| Share repurchases | — | — | — | — | — |
| Debt repayment | — | — | — | — | — |
| Net change in cash | — | — | — | — | — |
Frequently asked questions
How much free cash flow does ANRO generate?
ANRO produced $-51.79M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.
Is ANRO's balance sheet healthy?
ANRO holds $176.48M in cash and equivalents against $18.40M in long-term debt, on $151.14M of shareholder equity. Cash on hand exceeds long-term debt, so the balance sheet adds little financial risk to the thesis.